This includes for instance, selonsertib, an apoptosis signal-regulating kinase 1 (ASK1) inhibitor (Loomba et al., 2018) indicated for the treatment of non-alcoholic steatohepatitis (NASH), nintedanib and masitinib, which are both inhibitors of tyrosine kinase receptors (Dubreuil et al., 2009; Papadopoulos and Lennartsson, 2018). This evidence concerns the gene MAP3K5 and metabolic dysfunction-associated steatohepatitis.